Lactic acid bacteria strains useful against urogenital pathogens and compositions containing same

Inactive Publication Date: 2008-01-24
MEDINOVA
View PDF6 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] These bacteria are further selected for their ability to modulate a humoral and/or cellular immune response in the urogenital and/or gastrointestinal mucous membrane cells and to inhibit the inflammatory syndrome within said mucous membrane cells.
[0010] The invention also provides a method for establishing, maintaining or restoring a healthy urogenital flora in females throughout life, which comprises administering a pharmaceutical preparation comprising, in combination with a suitable galenical carrier, a therapeutically effective amount of at least one of the selected LAB strains.
[0011] The invention further refers to a method for preventing or treating urogenital infections in females which comprises administering a pharmaceutical preparation comprising, in combination with a suitable galenical carrier, a therapeutically effective amo

Problems solved by technology

Urogenital infections remain a common prob

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactic acid bacteria strains useful against urogenital pathogens and compositions containing same
  • Lactic acid bacteria strains useful against urogenital pathogens and compositions containing same

Examples

Experimental program
Comparison scheme
Effect test

example 1

1. Adhesion Capacity of L. Jensenii KS 119.1 and KS 130.1, L. Crispatus KS 116.1 and L. Gasseri KS 124.3 onto HeLa and Caco-2 / TC7 Cells.

[0079] The level of adhesion of the above strains was determined after the cells were inoculated with four concentrations of lactobacilli (5×107; 1×108; 5×108; 1×109 CPU / well). Generally, a concentration-dependent adhesion was observed.

[0080] In cervix HeLa cells, adhesion levels observed show that all the tested strains are adhering. The L. jensenii KS 119.1 and KS 130.1 strains appeared the best adhering strains (7.5 log CFU / ml at 5×108 CPU / well) as compared with the control adhering strains, L. casei rhamnosus GG and L. rhamnosus GR1 strains.

[0081] In intestinal Caco-2 / TC7 cells, adhesion levels observed show that all the Medinova strains are adhering. The L. crispatus KS 116,1, L. jensenii 119.1,129.1 and KS 130.1, L. gasseri 124.3 strains appeared the best adhering strains (7.5-8 logs CFU / ml at 5×108 CPU / well) as compared with the control a...

example 2

1. Activity of L. gasseri KS 124.3, L. helveticus KS 300 and L. acidophilus KS 400 on the Growth of Urogenital and Intestinal Pathogens.

[0100] It has been examined whether the strains referred to here above are active against the growth of Staphylococcus aureus, Streptococcus agalactiae, Candida albicans and uropathogenic and diarrheagenic E. coli strains IH11128 and 7372. The growth of pathogens was measured at 5, 8, 18 and 24 h.

[0101] No activity was developed against Streptococcus agalactiae and Candida albicans by L. gasseri KS 124.3, L. helveticus KS 300 and L. acidophilus KS 400 as well as by the control strains GR-1 and RC-14.

[0102] Concerning Staphylococcus aureus, the control L. rhamnosus strain GR-1 and L. fermentum strain RC-14 efficiently inhibited the growth of the bacteria. Similarly, L. gasseri KS 124.3, L. helveticus KS 300 and L. acidophilus KS 400 inhibited the growth of Staphylococcus aureus and showed a decrease in the viable bacteria number. When activities ...

example 3

1. Killing Activity of L. jensenii KS 121.1 and KS 122.1, L. gasseri KS 120.1 and L. helveticus KS 300 Against Urogenital and Intestinal Pathogens.

[0112] It has been examined whether said lactobacillus strains are active on the viability of Streptococcus agalactiae, Candida albicans, uropatho genie E. coli H11128, Gardnerella vaginalis, Prevotella bivia and Salmonella enterica Typhimurium. The effect on viability of pathogens was measured at 4 h of contact. Concerning both Streptococcus agalactiae and Candida albicans none of the tested lactobacilli showed an activity.

[0113] For uropathogenic E. coli strains IH11128, L. jensenii KS 121.1 and KS 122.1 showed no activity whereas, in contrast, L. gasseri KS 120.1 decreased efficiently (4 logs) the viability of E. coli in unshaken conditions. L. helveticus KS 300 and the L. fermentum RC-14 control strain decreased of 2 logs the viability of E. coli in unshaked conditions only.

[0114] Concerning Gardnerella vaginalis, both L. jensenii...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method for preventing or treating urogenital infections in females, which comprises administering a pharmaceutical preparation comprising, in combination with a suitable galenical carrier, a therapeutically effective amount of at least one lactic acid bacteria strain of the genus L. acidophilus, L. crispatus, L. gasseri, L. helveticus and L. jensenii selected for their ability to kill urogenital and/or gastrointestinal pathogens and their ability to inhibit internalization of urogenital and/or gastrointestinal pathogens within vaginal epithelial cells, as well as for their ability to modulate a humoral and/or cellular immune response at the vaginal and/or gastrointestinal level, in particular to inhibit the inflammatory syndrome as well as the infectious syndrome.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of international application PCT / EP2005 / 011150 filed October 17, 2005, the entire content of which is expressly incorporated herein.FIELD OF THE INVENTION [0002] This invention refers to the treatment of infectious troubles caused by various pathogens in humans, more specifically to the prevention and / or the treatment of urogenital infections in females. BACKGROUND OF THE INVENTION [0003] Several experimental and clinical studies have assessed already the potential of certain lactobacilli in the prevention or treatment of certain genito-urinary tract infections such as bacterial vaginitis, vaginosis, or urinary tract infections and relevant therapy is applied for many decades already. [0004] Urogenital infections remain a common problem, particularly in the female population. Bacterial adherence to the urogenital epithelium is recognized as an important mechanism in the initiation and pathogenesis of u...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A01N63/00A01P15/00C12N1/20A61K35/747
CPCA23L1/3014A23L2/382A23V2002/00A61K9/02A61K35/747C12R1/225C12R1/23A61K2300/00A23V2200/32A23V2200/3204A23L33/135A61P1/00A61P13/00A61P13/02A61P13/10A61P15/00A61P15/02A61P29/00A61P31/00A61P31/04A61P31/10A61P37/02A61P37/04Y02A50/30C12R2001/23C12N1/205C12R2001/225A61K9/0034A61K9/0053A61K9/48A61K2035/115
Inventor GRAF, FEDERICOGROB, PHILIPPBRASSART, DOMINIQUE
Owner MEDINOVA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap